HDAC9 and neoplasm: Preclinical studies have shown that HDAC inhibitors and DNMT inhibitors, which target histone hypo-acetylation and DNA hyper-methylation respectively, are capable of reprogramming PDAC cells and inhibiting tumor growth in mice [21, 22].